Relationships between abnormal MMP2 expression and prognosis in gastric cancer: A meta-analysis of cohort studies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 4, 2014, Pages 166-172

  Wang, He Ling ^a   Zhou, Ping Yi ^a   Zhang, Yu ^a   Liu, Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Matrix metalloproteinases 2; Meta analysis; Prognosis

Indexed keywords

GELATINASE A; MMP2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; ASIAN; CANCER PATIENT; CANCER PROGNOSIS; CAUCASIAN; ETHNICITY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; BIOSYNTHESIS; COHORT ANALYSIS; ENZYMOLOGY; META ANALYSIS; PROGNOSIS; STOMACH TUMOR;

COHORT STUDIES; HUMANS; MATRIX METALLOPROTEINASE 2; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900490949     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1608     Document Type: Article

References (31)

1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009;472:467.
2. Knight G, Earle CC, Cosby R, et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: A systematic review and practice guideline for North America. Gastric Cancer 2013;16:28.
3. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: A global overview. Int J Cancer 2009;125:666.
4. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v50.
5. Bonequi P, Meneses-Gonzalez F, Correa P, et al. Risk factors for gastric cancer in Latin America: A meta-Analysis. Cancer Causes Control 2013;24:217.
6. Milne AN, Carneiro F, O'Morain C, et al. Nature meets nurture: Molecular genetics of gastric cancer. Hum Genet 2009;126:615.
7. Wu WK, Cho CH, Lee CW, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010;295:144.
8. Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M. Gastric cancer-The role of matrix metalloproteinases in tumor progression. Clin Chim Acta 2011;412:1725.
9. Goncalves AN, Meschiari CA, Stetler-Stevenson WG, et al. Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli. J Biotechnol 2012;157:20.
10. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: A mini-review. Med Sci Monit 2009;15:RA32.
11. Emara M, Cheung PY, Grabowski K, et al. Serum levels of matrix metalloproteinase-2 and-9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin Chem Lab Med 2009;47:993.
12. Noh S, Jung JJ, Jung M, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology 2011;58:2015.
13. Mroczko B, Lukaszewicz-Zajac M, Gryko M, et al. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol 2011;49:125.
14. Wang LB, Jiang ZN, Fan MY, et al. Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer. World J Gastroenterol 2008;14:1612.
15. Huang KJ, Sui LH. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and Ecadherin in epithelial ovarian cancer.Med Oncol 2012;29:318.
16. Shou ZX, He QJ, Chu YQ, et al. Expression of matrix metalloproteinase-2 and insulin-like growth factor-1 in gastric carcinoma and their clinicopathological significance. Chin J Surg 2010;48:774.
17. Wang G, Wang W, Zhou J, et al. Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark 2013;13:21.
18. Xu XF, Lin JC, Wu N, et al. Clinical relationship between expression of MMP-2 and TIM-3 in cardia carcinoma. Cancer Res Clin 2010;22:319.
19. Zhao ZS, Wang YY, Chu YQ, et al. SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010;16:260.
20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol 2010;25:603.
21. Zintzaras E, Ioannidis JP. HEGESMA: Genome search metaanalysis and heterogeneity testing. Bioinformatics 2005;21: 3672.
22. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-Analysis. JAMA 2006;295:676.
23. Shi LH, HuangWB, Zhao GH, et al. The relationship between MMP-2,TIMP-2 expression and lymph node metastasis and prognosis of gastric cancer. J Practical Oncol 2001;16:399.
24. Wu JD, Zhuang YZ, Huang MS, et al. Relationship between expression of MMPs in invasiveness and metastasis of gastric carcinoma as well as patients survival. Practical J Cancer 2005;20:487.
25. Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008;23:917.
26. Allgayer H, Babic R, Beyer BC, et al. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 1998;55:152.
27. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: An application of gene-expression and tissue array techniques. Ann Surg 2006;243:64.
28. Hwang TL, Lee LY, Wang CC, et al. Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther Med 2010;1:789.
29. Mrena J, Wiksten JP, Nordling S, et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 2006;59:618.
30. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29.
31. Sato H, Takino T. Coordinate action of membrane-Type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 2010;101:843.